Moreover, a triple-blind clinical trial conducted in Brazil by Batista et al. assessed both acute and chronic FFAR4 activation following ω-3 supplementation in PBMCs from patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and overweight. This evidence concerns the gene FFAR4 and metabolic dysfunction-associated steatotic liver disease.